In addition, recent report shown that BAY 1143269, a novel MNK1 inhibitor, has a strongly efficacy in monotherapy in NSCLC both in vitro and in vivo, by regulating cell cycle regulation, apoptosis, immune response and EMT29. The gene discussed is MKNK1; the disease is non-small cell lung carcinoma.